A nurse is collecting data from a newborn immediately after delivery by a client who was at 42 weeks of gestation. Which of the following findings should the nurse expect?

Choice A reason:

Stop breastfeeding. This is the correct answer because newborns and infants with galactosemia cannot metabolize galactose, a sugar found in milk and lactose-containing formulas, including breast milk. Galactose can build up in their blood and cause serious complications such as liver damage, cataracts, brain damage, and even death. Therefore, the therapeutic management for this newborn is to stop breastfeeding and switch to a soy or elemental formula that contains no galactose.

Choice B reason:

Add amino acids to the breast milk. This is incorrect because adding amino acids to breast milk will not prevent the accumulation of galactose in the newborn's blood. Amino acids are the building blocks of proteins, not sugars. Adding amino acids to breast milk will not change its galactose content or help the newborn metabolize it.

Choice C reason:

Substitute a lactose-containing formula for breast milk. This is incorrect because lactose is a disaccharide composed of glucose and galactose. Lactose-containing formulas will also expose the newborn to galactose, which they cannot break down. Lactose-containing formulas should be avoided in newborns and infants with galactosemia.

Choice D reason:

Give the appropriate enzyme along with breast milk. This is incorrect because there is no enzyme therapy available for galactosemia. Galactosemia is caused by a genetic defect in one of the enzymes involved in the breakdown of galactose, such as galactose-1-phosphate uridyltransferase (GALT), galactokinase (GALK), or uridine diphosphate galactose-4-epimerase (GALE). Giving an enzyme along with breast milk will not correct this defect or prevent the harmful effects of galactose accumulation.

Choice A reason:

Infection is not prevented by vitamin K administration. Vitamin K is needed for blood clotting, not for fighting infections. Newborns are given vitamin K injections to prevent a serious disease called hemorrhagic disease of the newborn (HDN), which is caused by bleeding in the brain or other organs.

Choice B reason:

Hyperbilirubinemia is not prevented by vitamin K administration. Hyperbilirubinemia is a condition in which there is too much bilirubin in the blood, causing jaundice. Bilirubin is a yellow pigment that is produced when red blood cells break down. Vitamin K does not affect the production or breakdown of bilirubin.

Choice C reason:

Bleeding is prevented by vitamin K administration. Vitamin K is needed for the synthesis of several clotting factors that help stop bleeding when there is an injury. Newborns have very low levels of vitamin K in their bodies because they do not get enough from the placenta or breast milk, and they do not have enough bacteria in their intestines to produce it. This puts them at risk for VKDB, which can cause life-threatening bleeding in the brain or other organs.

Choice D reason:

Potassium deficiency is not prevented by vitamin K administration. Potassium is an electrolyte that is important for nerve and muscle function, as well as fluid balance. Vitamin K does not affect the absorption or excretion of potassium.